Optimizing Epilepsy Management In The Elderly: A Cohort Study Comparing Brivacetam And Levetiracetam
DOI:
https://doi.org/10.63682/jns.v14i32S.7388Keywords:
Epilepsy, geriatrics, levetiracetam, brivaracetam, quality of life, cognition, side effects, compliance, and seizure control are all important termsAbstract
Background: Managing epilepsy in older people is more difficult because of changes in how drugs work with age, cognitive decline, and a greater risk of side effects. Levetiracetam and Brivaracetam are newer-generation antiepileptic drugs (AEDs) that are often prescribed. However, there is still not enough real-world data comparing their safety, tolerability, and effects on quality of life in older people.
Objective: To see how levetiracetam and brivaracetam monotherapy affect the quality of life, seizure control, cognition, mood, frailty, and safety of older people with epilepsy over a 24-week treatment period.
Methods: This was a 24-week, open-label, observational cohort study done at a tertiary care hospital in Chennai, India. We enrolled 80 people with epilepsy who were at least 65 years old and divided them into two groups of 40 based on whether they were currently taking levetiracetam or brivaracetam. The Older People's Quality of Life Questionnaire (OPQOL-35), the Mini-Mental State Examination (MMSE), the Geriatric Depression Scale (GDS-15), the Clinical Frailty Scale (CFS), and seizure diaries were all used for baseline and follow-up assessments. We checked compliance every month and kept track of any bad things that happened during the study.
Results: At 24 weeks, both groups had significant improvements in their OPQOL-35 scores, but brivaracetam had a bigger mean improvement than levetiracetam (Δ = 5.4 points; p = 0.038). Both groups saw improvements in cognitive function and mood, but brivaracetam had a statistically significant edge in MMSE and GDS-15 change scores. Adverse events happened more often in the levetiracetam group (35%) than in the brivaracetam group (20%). Most of these events were mild neuropsychiatric or systemic symptoms.
Conclusion: Brivaracetam was better tolerated and led to bigger improvements in quality of life and cognitive measures than levetiracetam. This supports its use in older people with epilepsy.
Downloads
Metrics
References
Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: Etiology and management. Epilepsia. 2005;46 Suppl 12:41-47.
Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019-1030.
Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993;34(3):453-468.
Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482.
Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology. 2004;62(5 Suppl 2):S24-S29.
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512-521.
Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther. 2007;113(1):165-183.
Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology. 2004;62(5 Suppl 2):S24-S29.
Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019-1030.
Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993;34(3):453-468.
Forsgren L, Beghi E, Oun A, Sillanpää M. The epidemiology of epilepsy in Europe – a systematic review. Eur J Neurol. 2005;12(4):245-253.
Forsgren L, Beghi E, Oun A, Sillanpää M. The epidemiology of epilepsy in Europe – a systematic review. Eur J Neurol. 2005;12(4):245-253.
Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019-1030.
Galovic M, Döhler N, Erdélyi-Canavese B, et al. Prediction of late seizures after ischemic stroke with a novel prognostic model (the SeLECT score): A multivariable prediction model development and validation study. Lancet Neurol. 2018;17(2):143-152.
Pandis D, Scarmeas N. Seizures in Alzheimer's disease: clinical and epidemiological data. Epilepsy Curr. 2012;12(5):184-187.
Beghi E, Shorvon S. Antiepileptic drugs and the immune system. Epilepsia. 2011;52 Suppl 3:40-44.
Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther. 2007;113(1):165-183.
Tanaka T, Koike T, Tsuji S. Age-specific incidence of epilepsy in a general population of Japan: A longitudinal observation of a cohort of 197,587 subjects. J Neurol Sci. 2015;355(1-2):88-93.
Galovic M, Döhler N, Erdélyi-Canavese B, et al. Prediction of late seizures after ischemic stroke with a novel prognostic model (the SeLECT score): A multivariable prediction model development and validation study. Lancet Neurol. 2018;17(2):143-152.
Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: Etiology and management. Epilepsia. 2005;46 Suppl 12:41-47.
Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology. 2002;58(8 Suppl 5):S2-S8.
Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology. 2004;62(5 Suppl 2):S24-S29.
Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: Etiology and management. Epilepsia. 2005;46 Suppl 12:41-47.
Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: Etiology and management. Epilepsia. 2005;46 Suppl 12:41-47.
Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology. 2004;62(5 Suppl 2):S24-S29.
Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019-1030.
Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-1276.
Faught E. Adverse drug reactions in elderly people: a growing problem. BMJ. 2001;323(7310):122-123.
Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890-1898.
Helmstaedter C, Mihov Y, Toliat MR, et al. Adverse effects of levetiracetam on cognitive function in elderly patients. Epilepsy Behav. 2008;13(2):324-326.
Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive brivaracetam for the treatment of partial-onset seizures: pooled analysis of three phase III studies. Epilepsia. 2016;57(7):1136-1145.
Beghi E, Giussani G, Sander JW. The natural history and prognosis of epilepsy. Epileptic Disord. 2015;17(3):243-253.
Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology. 2004;62(5 Suppl 2):S24-S29.
Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019-1030.
Steinhoff BJ, Klein P, Klitgaard H, et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review. Epilepsy & Behavior. 2021;118:107939. doi:10.1016/j.yebeh.2021.107939
Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia. 2015;56(3):450-459. doi:10.1111/epi.12926
Meador KJ, Gevins A, Leese PT, Otoul C, Loring DW. Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia. 2011;52(2):264-272. doi:10.1111/j.1528-1167.2010.02746.x
Mula M, Trimble MR. Antiepileptic Drug-Induced Cognitive Adverse Effects: Potential Mechanisms and Contributing Factors. CNS Drugs. 2009;23(2):121-137. doi:10.2165/00023210-200923020-00003
Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385-407. doi:10.1177/1756285611417920
Pugh MJV, Copeland LA, Zeber JE, et al. The Impact of Epilepsy on Health Status among Younger and Older Adults. Epilepsia. 2005;46(11):1820-1827. doi:10.1111/j.1528- 1167.2005.00291.x
Mula M, Sander JW. Negative Effects of Antiepileptic Drugs on Mood in Patients with Epilepsy: Drug Safety. 2007;30(7):555-567. doi:10.2165/00002018-200730070-00001
Kasper BS, Vaccarella M. Is epilepsy surgery a threat to a patient’s self? A conversation. Epilepsy & Behavior. 2017;75:264-268. doi:10.1016/j.yebeh.2017.05.029
Klein P, Schiemann J, Sperling MR, et al. A randomized, double‐blind, placebo‐ controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizures. Epilepsia. 2015;56(12):1890-1898. doi:10.1111/epi.13212
Subramonian A, Farrah K. Brivaracetam versus Levetiracetam for Epilepsy: A Review of Comparative Clinical Safety. Canadian Agency for Drugs and Technologies in Health; 2020. Accessed April 13, 2025. http://www.ncbi.nlm. nih.gov/books/NBK567269/
Lavan AH, Gallagher P, O’Mahony D. Inter-rater reliability of STOPPFrail [Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy] criteria amongst 12 physicians. Eur J Clin Pharmacol. 2018;74(3):331-338. doi:10.1007/s00228- 017-2376-2
Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. The Lancet Neurology. 2009;8(11):1019-1030. doi:10.1016/S1474-4422(09)70240-6
Rockwood K, Theou O. Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources. Can Geri J. 2020;23(3):254-259. doi:10.5770/cgj.23.463
Pandya R, Sundaram PK, Baghel SS. Comparison of Effectiveness of Brivaracetam and Levetiracetam for Prophylaxis of Early Post-Traumatic Seizures: A Prospective Comparative Interventional Study. Asian J Neurosurg. 2024;19(4):728-734. doi:10.1055/s-0044-1790516
Feyissa AM. Brivaracetam in the treatment of epilepsy: a review of clinical trial data.
NDT. 2019;Volume 15:2587-2600. doi:10.2147/NDT.S143548
Trinka E, Tsong W, Toupin S, et al. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization. Epilepsy Res. 2020;166:106403. doi:10.1016/j.eplepsyres.2020.106403.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
